Podentamig

N/A

Report date: 2026/03/19 16:46:18

Base Information

Drug NamePodentamig
Drug Alias NameTriTACHPN-217BCMA TriTAC
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-cell maturation protein modulatorsAnti-CD3
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHarpoon TherapeuticsAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesHarpoon Therapeutics IncAbbvie Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A